PL2655388T3 - Selektywne inhibitory glikozydazy i ich zastosowania - Google Patents

Selektywne inhibitory glikozydazy i ich zastosowania

Info

Publication number
PL2655388T3
PL2655388T3 PL11850773.0T PL11850773T PL2655388T3 PL 2655388 T3 PL2655388 T3 PL 2655388T3 PL 11850773 T PL11850773 T PL 11850773T PL 2655388 T3 PL2655388 T3 PL 2655388T3
Authority
PL
Poland
Prior art keywords
glycosidase inhibitors
selective glycosidase
selective
inhibitors
glycosidase
Prior art date
Application number
PL11850773.0T
Other languages
English (en)
Inventor
Ramesh Kaul
Ernest J. Mceachern
Changwei Mu
Harold G. Selnick
David J. Vocadlo
Yaode Wang
Zhongyong Wei
Yuanxi Zhou
Yongbao Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2011/074569 external-priority patent/WO2012159262A1/en
Application filed filed Critical
Publication of PL2655388T3 publication Critical patent/PL2655388T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
PL11850773.0T 2010-12-23 2011-12-21 Selektywne inhibitory glikozydazy i ich zastosowania PL2655388T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426773P 2010-12-23 2010-12-23
PCT/CN2011/074569 WO2012159262A1 (en) 2011-05-24 2011-05-24 Selective glycosidase inhibitors and uses thereof
US201161507684P 2011-07-14 2011-07-14

Publications (1)

Publication Number Publication Date
PL2655388T3 true PL2655388T3 (pl) 2016-12-30

Family

ID=46312954

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11850773.0T PL2655388T3 (pl) 2010-12-23 2011-12-21 Selektywne inhibitory glikozydazy i ich zastosowania

Country Status (27)

Country Link
US (2) US9243020B2 (pl)
EP (1) EP2655388B1 (pl)
JP (2) JP5861194B2 (pl)
KR (1) KR101979036B1 (pl)
CN (1) CN103339138B (pl)
AR (1) AR085004A1 (pl)
AU (1) AU2011349021B2 (pl)
BR (1) BR112013016179A2 (pl)
CA (1) CA2822493C (pl)
CO (1) CO6821931A2 (pl)
CY (1) CY1118157T1 (pl)
DK (1) DK2655388T3 (pl)
ES (1) ES2589164T3 (pl)
HK (1) HK1191016A1 (pl)
HR (1) HRP20161079T1 (pl)
HU (1) HUE030624T2 (pl)
IL (1) IL227055A (pl)
LT (1) LT2655388T (pl)
MX (1) MX343822B (pl)
MY (1) MY165728A (pl)
NZ (1) NZ612703A (pl)
PL (1) PL2655388T3 (pl)
PT (1) PT2655388T (pl)
RU (1) RU2609210C2 (pl)
TW (1) TWI572609B (pl)
WO (1) WO2012083435A1 (pl)
ZA (1) ZA201305531B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006220187B2 (en) * 2005-03-01 2012-11-08 Simon Fraser University Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
EP2322529B1 (en) 2006-08-31 2017-12-06 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2010012107A1 (en) * 2008-08-01 2010-02-04 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US9120781B2 (en) 2010-05-11 2015-09-01 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2012061927A1 (en) * 2010-11-08 2012-05-18 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof
NZ612703A (en) * 2010-12-23 2015-07-31 Merck Sharp & Dohme Selective glycosidase inhibitors and uses thereof
WO2012126091A1 (en) 2011-03-24 2012-09-27 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2691407B1 (en) 2011-03-31 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2726492B1 (en) 2011-06-27 2017-11-01 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
RU2625308C2 (ru) * 2011-06-27 2017-07-13 Алектос Терапьютикс Инк. Селективные ингибиторы гликозидазы и их применение
WO2013000085A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
JP5893738B2 (ja) 2011-08-25 2016-03-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ グリコシダーゼ阻害剤としてのピラノ［３，２−ｄ］［１，３］チアゾール
US9670195B2 (en) 2012-08-31 2017-06-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
EP2890675A4 (en) 2012-08-31 2016-01-13 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
AU2013337570B2 (en) * 2012-10-31 2018-01-18 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014100934A1 (en) 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
CN107108601B (zh) 2014-08-28 2021-08-20 阿森纽荣股份公司 糖苷酶抑制剂
KR101777164B1 (ko) 2015-07-20 2017-09-11 순천향대학교 산학협력단 O-GlcNAc 트랜스퍼레즈 억제제용 UDP-GlcNAc의 C1-포스포네이트 유도체
AR106977A1 (es) * 2015-12-14 2018-03-07 Amicus Therapeutics Inc Compuestos para el tratamiento de la enfermedad de alzheimer y/o la angiopatía amiloide cerebral
EP3419976B1 (en) 2016-02-25 2021-04-07 Asceneuron SA Acid addition salts of piperazine derivatives
US10556902B2 (en) 2016-02-25 2020-02-11 Asceneuron Sa Glycosidase inhibitors
MA43677A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
CN107814773B (zh) * 2017-11-13 2020-05-22 西安交通大学 含有喹唑啉酮的二芳基脲类化合物及其制备方法和应用
AU2019289969A1 (en) * 2018-06-20 2020-12-17 Janssen Pharmaceutica Nv OGA inhibitor compounds
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
CA3138726A1 (en) * 2019-05-10 2020-11-19 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof
CN111956656B (zh) * 2020-08-28 2021-10-15 河北大学 Oga抑制剂在制备抗肿瘤药物中的应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS423500Y1 (pl) 1964-02-29 1967-03-01
DE2632243C3 (de) 1976-07-17 1979-08-30 Heidelberger Druckmaschinen Ag, 6900 Heidelberg Auf variable Bogenlängen einstellbare Umführtrommel für Druckmaschinen
DE3620645A1 (de) 1985-12-20 1987-07-02 Bayer Ag 3-amino-4,5-dihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung
EP0243686B1 (en) 1986-03-27 1992-07-15 Sumitomo Pharmaceuticals Company, Limited Beta-lactam compounds, and their production
SU1441749A1 (ru) * 1987-03-16 1996-01-10 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 2-АМИНО-5,5-ДИМЕТИЛ-4,5-ДИГИДРО-7Н-ПИРАНО [4,3-d] ТИАЗОЛ, ОБЛАДАЮЩИЙ ТРАНКВИЛИЗИРУЮЩЕЙ АКТИВНОСТЬЮ
JPS6461459A (en) 1987-08-28 1989-03-08 Nippon Shinyaku Co Ltd Moranoline derivative
JPH01180894A (ja) 1988-01-07 1989-07-18 Wako Pure Chem Ind Ltd アミノ糖誘導体の新規な製造法
GB8900719D0 (en) 1989-01-13 1989-03-08 Nycomed As Compounds
US5079254A (en) 1990-06-04 1992-01-07 Merrell Dow Pharmaceuticals Inc. Derivatives of 6-aminooctahydroindolizinetriol
WO1992003415A1 (en) 1990-08-14 1992-03-05 Nova Pharmaceutical Corporation Protein kinase c modulators
US5276120A (en) 1991-05-30 1994-01-04 The Scripps Research Institute Process for forming omega-deuxy-azasugars
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5451679A (en) 1994-03-08 1995-09-19 G. D. Searle & Co. 2-chloro and 2-bromo derivatives of 1,5-iminosugars
JPH07316178A (ja) 1994-05-25 1995-12-05 Sankyo Co Ltd 糖アミノオキサゾリン類
CN1131672A (zh) 1994-11-22 1996-09-25 生化学工业株式会社 氨基环戊烷衍生物
CA2235415A1 (en) 1995-09-08 1997-03-13 Novo Nordisk A/S 2-alkylpyrrolidines
DE69626660T2 (de) 1995-09-08 2003-08-21 Novo Nordisk As 2-alkylpyrrolidine
JPH09132585A (ja) 1995-11-10 1997-05-20 Shin Etsu Chem Co Ltd 新規アミノ糖及びキトオリゴ糖又はその類似オリゴ糖の製造方法
US6407103B2 (en) 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
JPH11349541A (ja) 1998-06-08 1999-12-21 Sankyo Co Ltd アロサミゾリン誘導体の新規な中間体
GB9818732D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collection of compounds
US6774140B1 (en) 1999-05-11 2004-08-10 The Scripps Research Institute Iminocyclitol inhibitors of hexoaminidase and glycosidase
CA2373183C (en) 1999-05-11 2009-12-08 The Scripps Research Institute Iminocyclitol inhibitors of hexoaminidase and glycosidase
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
JP4233262B2 (ja) 2001-03-14 2009-03-04 生化学工業株式会社 カルバ糖アミン誘導体及びそれを用いるグリコシダーゼ阻害剤
JP4036755B2 (ja) 2001-03-14 2008-01-23 電気化学工業株式会社 ヒアルロン酸又はヒアルロン酸誘導体の製造法
WO2003008379A1 (fr) 2001-06-08 2003-01-30 Mitsubishi Chemical Corporation Composes azasucre
JP4866515B2 (ja) 2001-07-02 2012-02-01 生化学工業株式会社 糖オキサゾリン誘導体の製造方法
US7214373B2 (en) 2001-07-24 2007-05-08 Yale University Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
CA2526173A1 (en) 2003-05-22 2004-12-02 The Hospital For Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
CN1548053A (zh) 2003-05-23 2004-11-24 华晶基因技术有限公司 黄芩甙作为治疗焦虑症的药物的新用途
CA2541100A1 (en) 2003-09-16 2005-03-24 Astrazenca Ab Quinazoline derivatives
WO2005072268A2 (en) 2004-01-20 2005-08-11 Optimer Pharmaceuticals, Inc. Treatment of degeneraative cartilage conditions in a mammal with glycosidase inhibitors
EP1734821A4 (en) 2004-04-14 2011-07-06 Uab Research Foundation ACTIVATORS OF HEXOSAMIN BINOSYNTHESIS AS AN INHIBITORS FOR INDUCED DAMAGE CAUSED BY ISCHEMIC SHOCK OR HEMORRHAGIC SHOCK
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
EP1773812A1 (en) 2004-07-23 2007-04-18 Bayer CropScience S.A. 3-pyridinylethylcarboxamide derivatives as fungicides
CA2579143A1 (en) 2004-09-13 2006-03-23 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7884115B2 (en) 2004-09-28 2011-02-08 Allergan, Inc. Methods and compositions for the treatment of pain and other neurological conditions
AU2006220187B2 (en) * 2005-03-01 2012-11-08 Simon Fraser University Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
AT502145B1 (de) 2005-03-24 2012-01-15 Univ Graz Tech Glycosidase-hemmendes iminoalditol
US7820699B2 (en) 2005-04-27 2010-10-26 Hoffmann-La Roche Inc. Cyclic amines
CN101296906A (zh) 2005-10-26 2008-10-29 贝林格尔·英格海姆国际有限公司 具有mch拮抗活性的(杂)芳基化合物及包含这些化合物的药物
WO2007067515A2 (en) 2005-12-05 2007-06-14 Academia Sinica Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics
EP2322529B1 (en) 2006-08-31 2017-12-06 Simon Fraser University Selective glycosidase inhibitors and uses thereof
CN107253970A (zh) 2006-08-31 2017-10-17 西蒙·弗雷瑟大学 选择性糖苷酶抑制剂及其用途
US8258307B2 (en) 2006-11-07 2012-09-04 University Of Tokyo Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same
WO2010012107A1 (en) 2008-08-01 2010-02-04 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US8541441B2 (en) 2008-08-01 2013-09-24 Simon Fraser University Selective glycosidase inhibitors and uses thereof
EP2323651A2 (en) 2008-08-05 2011-05-25 Summit Corporation Plc Compounds for the treatment of flaviviral infections
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
CA2737267A1 (en) 2008-09-16 2010-04-08 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2010049678A2 (en) 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
AT507745B1 (de) 2008-12-16 2012-01-15 Forschungsholding Tu Graz Gmbh Fluorophile glykosidasehemmer
WO2011060397A1 (en) 2009-11-16 2011-05-19 Schering Corporation Substituted amino heterocycles useful as hiv antagonists
US9120781B2 (en) 2010-05-11 2015-09-01 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US8901087B2 (en) 2010-11-08 2014-12-02 Merck Sharp & Dohme Corp. Selective glycosidase inhibitors and uses thereof
WO2012061972A1 (en) * 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
TW201249848A (en) 2010-11-08 2012-12-16 Merck Sharp & Dohme Selective glycosidase inhibitors and uses thereof
WO2012061927A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof
WO2012061971A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
NZ612703A (en) 2010-12-23 2015-07-31 Merck Sharp & Dohme Selective glycosidase inhibitors and uses thereof
GB201103526D0 (en) 2011-03-02 2011-04-13 Summit Corp Plc Selective glycosidase inhibitors and uses thereof
CN103547580B (zh) 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
WO2012126091A1 (en) 2011-03-24 2012-09-27 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2012129802A1 (en) 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof
EP2691407B1 (en) 2011-03-31 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013000085A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
RU2625308C2 (ru) 2011-06-27 2017-07-13 Алектос Терапьютикс Инк. Селективные ингибиторы гликозидазы и их применение
EP2726492B1 (en) 2011-06-27 2017-11-01 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013025452A1 (en) 2011-08-18 2013-02-21 Merck Sharp & Dohme Corp. Selective glycosidase inhibitors and uses thereof
JP5893738B2 (ja) 2011-08-25 2016-03-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ グリコシダーゼ阻害剤としてのピラノ［３，２−ｄ］［１，３］チアゾール
JP6178843B2 (ja) 2012-05-08 2017-08-09 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 透過性グリコシダーゼインヒビターおよびその用途
US9670195B2 (en) 2012-08-31 2017-06-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
EP2890675A4 (en) 2012-08-31 2016-01-13 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2890679A4 (en) 2012-08-31 2016-05-04 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2890678A4 (en) 2012-08-31 2016-01-27 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
AU2013337570B2 (en) 2012-10-31 2018-01-18 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014100934A1 (en) 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof

Also Published As

Publication number Publication date
CA2822493C (en) 2018-11-20
KR101979036B1 (ko) 2019-05-15
MY165728A (en) 2018-04-20
AU2011349021B2 (en) 2016-12-22
JP6322177B2 (ja) 2018-05-09
HUE030624T2 (en) 2017-05-29
KR20140041406A (ko) 2014-04-04
ES2589164T3 (es) 2016-11-10
HRP20161079T1 (hr) 2016-10-21
BR112013016179A2 (pt) 2018-07-10
HK1191016A1 (zh) 2014-07-18
JP2014501740A (ja) 2014-01-23
TW201249849A (en) 2012-12-16
EP2655388B1 (en) 2016-06-08
EP2655388A4 (en) 2014-06-18
TWI572609B (zh) 2017-03-01
EP2655388A1 (en) 2013-10-30
CY1118157T1 (el) 2017-06-28
DK2655388T3 (en) 2016-09-19
AR085004A1 (es) 2013-07-24
CA2822493A1 (en) 2012-06-28
JP2016033152A (ja) 2016-03-10
CN103339138B (zh) 2016-08-31
MX2013007434A (es) 2013-10-03
ZA201305531B (en) 2014-10-29
CO6821931A2 (es) 2013-12-31
WO2012083435A1 (en) 2012-06-28
US20140018309A1 (en) 2014-01-16
US9815861B2 (en) 2017-11-14
LT2655388T (lt) 2016-11-10
RU2609210C2 (ru) 2017-01-31
CN103339138A (zh) 2013-10-02
JP5861194B2 (ja) 2016-02-16
RU2013134345A (ru) 2015-01-27
US20160096858A1 (en) 2016-04-07
MX343822B (es) 2016-11-24
NZ612703A (en) 2015-07-31
PT2655388T (pt) 2016-09-06
IL227055A (en) 2016-11-30
US9243020B2 (en) 2016-01-26

Similar Documents

Publication Publication Date Title
HK1191016A1 (zh) 選擇性糖苷酶抑制劑及其用途
EP2569291A4 (en) GLYCOSIDASE SELECTIVE INHIBITORS AND USES THEREOF
EP2638052A4 (en) SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
GB201103526D0 (en) Selective glycosidase inhibitors and uses thereof
EP2723753A4 (en) SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2637503A4 (en) GLYCOSIDASE SELECTIVE INHIBITORS AND USES THEREOF
EP2890678A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2726468A4 (en) SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
PT2592933T (pt) Inibidores de mif e suas utilizações
EP2744338A4 (en) SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
EP2691407A4 (en) GLYCOSIDASE SELECTIVE INHIBITORS AND USES THEREOF
EP2890679A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
HK1198827A1 (en) Dyrk1 inhibitors and uses thereof dyrk1
EP2726492A4 (en) SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2688899A4 (en) GLYCOSIDASE SELECTIVE INHIBITORS AND USES THEREOF
EP2935283A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2847199A4 (en) PERMEABLE GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2321289A4 (en) GLYCOSIDASE SELECTIVE INHIBITORS AND USES THEREOF
EP2344452A4 (en) SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
EP2340250A4 (en) SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
EP2914604A4 (en) GLYCOSIDASE INHIBITORS AND ASSOCIATED APPLICATIONS
EP2890675A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2890676A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2556055A4 (en) SHIP INHIBITORS AND USES THEREOF
EP2608785A4 (en) LIPOMA CYCLES AND ITS USES